24 recruiting, 17 completed, 13 not yet recruiting, 4 enrolling by invitation. 14 Not applicable, 7 Phase 2, 6 Phase 1, 6 Phase 4, 5 Phase 3.
Follow Heart Failure With Preserved Ejection Fraction (HFPEF): new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction (HFPEF) trials Research Report on Heart Failure With Preserved Ejection Fraction (HFPEF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction empa plus vica, Comparator: empa 10 plus spironolactone - Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Not yet recruiting | Baim Institute for Clinical Research | 200 | 2027-03-01 | 2026-10-05 |
| Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction Heart Failure, Heart Failure, Diastolic | Not yet recruiting | Instituto Politécnico de Leiria | 200 | 2026-12-01 | 2026-02-24 | |
| Changes in Intramyocardial Fat Assessed by Cardiac CT Before and After Bariatric Surgery and Their Relationship With Cardiac Diastolic Function Obesity, Diastolic Dysfunction | Not yet recruiting | Itshak Amsalem | 150 | 2026-10-10 | 2026-10-09 | |
| Optimised Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease Multidisciplinary Cardio-Renal Care - Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF) | Not applicable | Recruiting | Odense University Hospital | 500 | 2026-10-01 | 2026-10-15 |
| Resmetirom in Patients With MASH and HFpEF Resmetirom, Placebo - MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 1 | Recruiting | Madrigal Pharmaceuticals, Inc. | 90 | 2026-09-01 | 2026-10-16 |
| Pilot Study of Endoscopic Sleeve Gastroplasty for Obese Patients With Heart Failure and Preserved Ejection Fraction Endoscopic sleeve gastroplasty (ESG) - Obesity (BMI>30), Heart Failure With Preserved Ejection Fraction (HFPEF) | Not applicable | Not yet recruiting | Cedars-Sinai Medical Center | 20 | 2026-09-01 | 2026-09-01 |
| Non-Interventional Study of Ferretab® Comp. (Ferrous Fumarate + Folic Acid Prolonged-Release Capsules) Effects in Adult Patients With Iron Deficiency Anemia and Cardiovascular Disease Iron Deficiency Anemia, Coronary Artery Disease | Not yet recruiting | Alcea | 389 | 2026-09-01 | 2026-09-16 | |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF Elecoglipron, Placebo - Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | Phase 3 | Recruiting | AstraZeneca | 6950 | 2026-08-24 | 2026-09-28 |
| Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF Tirzepatide, Structured Lifestyle Intervention - Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | Not yet recruiting | Yunlong Wang | 602 | 2026-08-01 | 2026-06-05 |
| Effects of a Multidisciplinary Integrated Care Model on Care Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Multidisciplinary Integrated Care Model (MICM), Usual Care - Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure | Not applicable | Not yet recruiting | Chimei Medical Center | 200 | 2026-08-01 | 2026-09-01 |
| AI-based Echocardiography for Detection of Cardiac Amyloidosis AI-based echocardiogram - Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF) | Not applicable | Not yet recruiting | Germans Trias i Pujol Hospital | 200 | 2026-07-01 | 2026-06-12 |
| HFpEF Phenotyping With Echo, Clinical, and Biomarkers Heart Failure With Preserved Ejection Fraction (HFPEF) | Not yet recruiting | University Of Perugia | 500 | 2026-06-02 | 2026-06-11 | |
| Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial Fecal Microbiota Transplantation (FMT) Capsules, Placebo capsules - Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 50 | 2026-06-01 | 2026-06-05 |
| PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF progressive resistance training, combined aerobic + resistance training - Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal) | Not applicable | Recruiting | Northwestern University | 30 | 2026-05-15 | 2026-08-24 |
| CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction HFpEF Observational Measurements - Heart Failure With Preserved Ejection Fraction (HFPEF) | Not yet recruiting | Herlev and Gentofte Hospital | 30000 | 2026-04-01 | 2026-03-25 | |
| Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap? Guideline-Directed Medical Therapy (GDMT) - Heart Failure, Acute Heart Failure | Phase 4 | Recruiting | IRCCS Policlinico S. Donato | 368 | 2026-03-31 | 2026-10-16 |
| Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction Percutaneous coronary intervention, Placebo procedure - Heart Failure With Preserved Ejection Fraction (HFPEF), Coronary Artery Disease | Phase 2 | Recruiting | King's College London | 350 | 2026-03-23 | 2026-05-01 |
| The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF Sacubitril / Valsartan - Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis | Phase 4 | Completed | University Clinical Hospital Mostar | 52 | 2026-01-30 | 2026-05-20 |
| Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF) | Not yet recruiting | Xinjiang Medical University | 600 | 2026-01-01 | 2026-01-21 | |
| Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin) - Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction | Not applicable | Recruiting | Nova Scotia Health Authority | 84 | 2026-01-01 | 2026-10-20 |
Showing 20 of 64. Sign in to see all of them.
Heart Failure (23) · Obesity (10) · Cardiovascular Diseases (6) · Atrial Fibrillation (4) · Heart Diseases (4) · Heart Failure, Diastolic (3) · Motor Activity (3) · Renal Insufficiency, Chronic (3) · Anemia, Iron-Deficiency (2) · Coronary Artery Disease (2) · Inflammation (2) · Sarcopenia (2) · Sprains and Strains (2) · Amyloid Neuropathies, Familial (1) · Bronchiolitis Obliterans Syndrome (1)
Cardiovascular Diseases (30) · Heart Diseases (30) · Pathological Conditions, Signs and Symptoms (23) · Nutritional and Metabolic Diseases (16) · Pathologic Processes (14) · Signs and Symptoms (12) · Body Weight (10) · Nutrition Disorders (10) · Overnutrition (10) · Overweight (10) · Metabolic Diseases (7) · Vascular Diseases (6) · Arrhythmias, Cardiac (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Urogenital Diseases (5)
Tirzepatide (3) · sacubitril and valsartan sodium hydrate drug combination (3) · Exercise Test (2) · Resistance Training (2) · AZD4831 (1) · AZD9977 (1) · Adrenergic beta-Antagonists (1) · Allopurinol (1) · Calcium Channel Blockers (1) · Capsules (1) · Catheter Ablation (1) · Clostridium perfringens epsilon-toxin (1) · Colchicine (1) · Digoxin (1) · Echocardiography (1)
AstraZeneca (5) · Cedars-Sinai Medical Center (2) · Manchester University NHS Foundation Trust (2) · National Medical Research Center for Therapy and Preventive Medicine (2) · Novartis Pharmaceuticals (2) · Xinjiang Medical University (2) · Alcea (1) · Ankara Ataturk Sanatorium Training and Research Hospital (1) · Baim Institute for Clinical Research (1) · BaroPace Inc. (1) · Brigham and Women's Hospital (1) · Chimei Medical Center (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · Dongying Zhang (1) · Duke University (1)
United States (22) · United Kingdom (8) · China (7) · Canada (6) · Italy (5) · Russia (5) · Argentina (4) · Denmark (4) · France (4) · Germany (4) · Japan (4) · South Korea (4) · Australia (3) · Austria (3) · Brazil (3)
Alberto Palazzuoli, MD (1) · Alexander H Maass, MD, PhD (1) · Barry Borlaug, MD (1) · C. Noel Bairey Merz, MD, FACC (1) · Chris Bleakley, PhD (1) · Chris Miller, MBChB FRCP (1) · Chris Miller, MBChB, MRCP (1) · Christopher M Hearon Jr, PhD (1) · Dalane Kitzman, MD (1) · David Han, M.D (1) · Deepika Laddu, PhD (1) · Dirk J Veldhuisen, van, MD, PhD (1) · Dongying Zhang, MD. Ph.D. (1) · Ellen C Keeley, MD, MS (1)
PMID 15753115, PMID 17630410, PMID 21745417, PMID 27695989, PMID 27925142, PMID 30051186, PMID 30853478, PMID 32331365, PMID 32683763, PMID 32865380, PMID 34935412, PMID 35363499, PMID 35956390, PMID 36262558, PMID 37212758, PMID 37827557, PMID 38059368, PMID 38508844, PMID 38699780, PMID 38802053, PMID 39141378, PMID 39185895, PMID 39211951, PMID 39212948, PMID 39443013, PMID 39495467, PMID 39505123, PMID 39551891, PMID 39555826, PMID 39556714, PMID 39566869, PMID 39603408, PMID 40010584, PMID 40162940, PMID 40174692, PMID 40268180, PMID 40701669, PMID 40886075, PMID 40903131, PMID 41451381, PMID 41711731, PMID 42142740, PMID 42348298, PMID 42417681, PMID 42480823
2018 (1), 2019 (1), 2023 (1), 2025 (1)